157 related articles for article (PubMed ID: 9522210)
1. Expression of CD44 in premalignant and malignant Barrett's oesophagus.
Lagorce-Pages C; Paraf F; Dubois S; Belghiti J; Fléjou JF
Histopathology; 1998 Jan; 32(1):7-14. PubMed ID: 9522210
[TBL] [Abstract][Full Text] [Related]
2. Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.
Lagorce-Pagès C; Paraf F; Wendum D; Martin A; Fléjou JF
Virchows Arch; 2004 May; 444(5):426-35. PubMed ID: 15045585
[TBL] [Abstract][Full Text] [Related]
3. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.
Lagorce C; Paraf F; Vidaud D; Couvelard A; Wendum D; Martin A; Fléjou JF
Histopathology; 2003 May; 42(5):457-65. PubMed ID: 12713622
[TBL] [Abstract][Full Text] [Related]
5. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
[TBL] [Abstract][Full Text] [Related]
6. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
[TBL] [Abstract][Full Text] [Related]
7. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
[TBL] [Abstract][Full Text] [Related]
8. Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum.
Jovanović I; Todorović V; Milosavljević T; Micev M; Pesko P; Bjelović M; Mouzas Y; Tzardi M
Vojnosanit Pregl; 2005 Dec; 62(12):879-85. PubMed ID: 16375215
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
10. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7.
Symmans PJ; Linehan JM; Brito MJ; Filipe MI
J Pathol; 1994 Jul; 173(3):221-6. PubMed ID: 7931842
[TBL] [Abstract][Full Text] [Related]
11. GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.
Pavlov K; Honing J; Meijer C; Boersma-van Ek W; Peters FT; van den Berg A; Karrenbeld A; Plukker JT; Kruyt FA; Kleibeuker JH
Dig Liver Dis; 2015 Jan; 47(1):73-80. PubMed ID: 25445407
[TBL] [Abstract][Full Text] [Related]
12. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
13. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations.
Fléjou JF; Paraf F; Muzeau F; Fékété F; Hénin D; Jothy S; Potet F
J Clin Pathol; 1994 Jan; 47(1):23-6. PubMed ID: 7907608
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD44H and CD44v3 in normal oesophagus, Barrett mucosa and oesophageal carcinoma.
Castellà E; Ariza A; Fernández-Vasalo A; Roca X; Ojanguren I
J Clin Pathol; 1996 Jun; 49(6):489-92. PubMed ID: 8763264
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD44v5 and -v6 in Barrett's carcinoma is not increased compared to that in nondysplastic Barrett's mucosa.
Menges M; Goebel R; Pueschel W; Zeitz M; Stallmach A
Exp Mol Pathol; 2002 Jun; 72(3):207-12. PubMed ID: 12009784
[TBL] [Abstract][Full Text] [Related]
16. The relationship of endocrine cells, dysplasia and carcinoembryonic antigen in Barrett's mucosa to adenocarcinoma of the oesophagus.
Griffin M; Sweeney EC
Histopathology; 1987 Jan; 11(1):53-62. PubMed ID: 2881873
[TBL] [Abstract][Full Text] [Related]
17. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
[TBL] [Abstract][Full Text] [Related]
18. TGR5 expression in benign, preneoplastic and neoplastic lesions of Barrett's esophagus: Case series and findings.
Marketkar S; Li D; Yang D; Cao W
World J Gastroenterol; 2017 Feb; 23(8):1338-1344. PubMed ID: 28293080
[TBL] [Abstract][Full Text] [Related]
19. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
20. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
